oncology medicines

Zetabin Injection (Gemcitabine Injection) – Product Description Zetabin Injection contains Gemcitabine, a nucleoside analog chemotherapy medicine used in the treatment of various types of cancers. It works by interfering with the growth and multiplication of cancer cells, helping to slow down or stop tumor progression. Gemcitabine is widely used as part of chemotherapy protocols for cancers including pancreatic cancer, non-small cell lung cancer, breast cancer, ovarian cancer, and bladder cancer. It may be used alone or in combination with other anticancer medicines depending on the patient's condition and treatment plan. Zetabin Injection is administered by a qualified healthcare professional through intravenous infusion. The dosage, frequency, and duration of treatment are determined by the treating oncologist based on cancer type, patient health condition, and response to therapy. Key Features: Contains Gemcitabine as the active anticancer ingredient Belongs to the class of antimetabolite chemotherapy agents Used in multiple solid tumor treatment protocols Administered through intravenous infusion under medical supervision Suitable for hospital and oncology center use Manufactured following stringent pharmaceutical quality standards Therapeutic Uses: Pancreatic Cancer Non-Small Cell Lung Cancer (NSCLC) Breast Cancer Ovarian Cancer Bladder Cancer Other malignancies as prescribed by an oncologist Important Note: Zetabin Injection is a prescription chemotherapy medicine and should only be used under the supervision of a qualified oncologist. Regular monitoring of blood counts and patient condition is required during treatment.

Zepirubin Injection contains Epirubicin, an anthracycline chemotherapy medicine used in the treatment of various cancers. It works by interfering with the growth and multiplication of cancer cells, helping to slow down or stop cancer progression. Epirubicin is commonly used as part of combination chemotherapy regimens and is administered under the supervision of an experienced oncologist. It is widely used in the management of breast cancer and other solid tumors where anthracycline-based therapy is clinically appropriate. Key Features: Contains Epirubicin Hydrochloride as the active ingredient Belongs to the Anthracycline class of anticancer medicines Injectable formulation for hospital and oncology center use Used in combination chemotherapy protocols Helps inhibit cancer cell growth and DNA replication Manufactured under strict pharmaceutical quality standards Therapeutic Uses: Breast Cancer Gastric Cancer Ovarian Cancer Lung Cancer Soft Tissue Sarcoma Other solid tumors as determined by an oncologist Product Information: Brand Name: Zepirubin Active Ingredient: Epirubicin Hydrochloride Dosage Form: Injection Therapeutic Class: Oncology / Chemotherapy Medicine Route of Administration: Intravenous infusion (administered by healthcare professionals) Note: Zepirubin Injection should only be used under the supervision of a qualified oncologist. Dosage, treatment cycles, and monitoring requirements are determined based on the patient's condition and response to therapy.

Zefinib Tablet 250 mg contains Gefitinib, a targeted anticancer medicine belonging to the class of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). It works by blocking EGFR signals that contribute to the growth and multiplication of certain cancer cells, helping to slow tumor progression. Gefitinib is primarily used in the treatment of non-small cell lung cancer (NSCLC), especially in patients whose tumors have specific EGFR mutations. It provides a targeted treatment approach by acting on cancer cells with these genetic changes. Zefinib Tablet is taken orally and should be used strictly under the supervision of an experienced oncologist. The treatment duration and dosage may vary depending on the patient's condition, cancer stage, and response to therapy. Key Features: Contains Gefitinib 250 mg Targeted therapy for EGFR-mutated cancers Belongs to the EGFR Tyrosine Kinase Inhibitor (TKI) class Oral tablet formulation for convenient administration Used in advanced oncology treatment protocols Manufactured under quality-controlled pharmaceutical standards Therapeutic Uses: EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Advanced or metastatic lung cancer management (as prescribed) Note: Zefinib Tablet should only be used under the guidance of a qualified oncologist. Regular monitoring and medical follow-up are required during treatment to evaluate response and manage possible adverse effects.

Zedaunor Injection 20 mg contains Daunorubicin, an anthracycline chemotherapy medicine used in the treatment of various blood cancers. It works by interfering with DNA replication inside cancer cells, helping to prevent their growth and multiplication. Daunorubicin is primarily used as part of combination chemotherapy regimens for the treatment of acute leukemias, especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is administered by qualified healthcare professionals in specialized oncology settings. Zedaunor Injection is given through intravenous administration under strict medical supervision. The dosage and treatment schedule are determined by the treating oncologist based on the patient's condition, cancer type, treatment protocol, and overall health status. Key Features: Contains Daunorubicin 20 mg Belongs to the Anthracycline class of chemotherapy medicines Used in hematological malignancies (blood cancers) Injectable formulation for hospital and oncology center use Helps inhibit cancer cell growth by affecting DNA function Manufactured under stringent pharmaceutical quality standards Therapeutic Uses: Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL) Other hematological cancers as recommended by an oncologist Note: Zedaunor Injection should only be administered by trained healthcare professionals. Patients require appropriate monitoring during treatment, including blood counts and cardiac function assessments, as advised by the treating physician.

Zaxotein Injection 100 mg contains Albumin-Bound Paclitaxel (Nab-Paclitaxel) 100 mg, an advanced formulation of the chemotherapy medicine paclitaxel. It belongs to the taxane class of anticancer agents and is designed to interfere with cancer cell division, helping to slow down or stop the growth of malignant cells. Albumin-bound paclitaxel uses an albumin-based delivery system that helps transport paclitaxel to tumor tissues. It is used in the treatment of various solid tumors, including breast cancer, non-small cell lung cancer, pancreatic cancer, and other cancers where taxane therapy is considered appropriate. Zaxotein Injection is administered by intravenous infusion under the supervision of qualified oncology professionals. The dosage schedule is determined by the treating oncologist based on the patient's cancer type, treatment plan, and overall health condition. Key Features: Contains Albumin-Bound Paclitaxel (Nab-Paclitaxel) 100 mg Advanced taxane-based chemotherapy formulation Used in multiple solid tumor treatment protocols Helps inhibit cancer cell growth and division Intravenous formulation for hospital and oncology center use Manufactured under strict pharmaceutical quality standards Suitable for oncology departments, hospitals, and specialized cancer care facilities Therapeutic Uses: Breast Cancer Non-Small Cell Lung Cancer (NSCLC) Pancreatic Cancer Other solid tumors as recommended by an oncologist Note: Zaxotein Injection should only be administered under the supervision of a qualified healthcare professional. Patients require regular monitoring for treatment response and possible chemotherapy-related adverse effects.

Zabiteron Tablet 250 mg contains Abiraterone Acetate 250 mg, an oral anticancer medicine belonging to the class of androgen biosynthesis inhibitors. It is primarily used in the treatment of advanced prostate cancer, particularly in patients with metastatic prostate cancer where reducing androgen production can help slow cancer progression. Abiraterone Acetate works by inhibiting the CYP17 enzyme, which plays an important role in androgen production. By reducing androgen levels in the body, Zabiteron helps limit the growth and spread of prostate cancer cells that depend on male hormones for development. Zabiteron is generally prescribed along with corticosteroid therapy (such as prednisone/prednisolone) and is used under the supervision of an experienced oncologist. The dosage, treatment duration, and monitoring schedule depend on the patient's medical condition and response to therapy. Key Features: Contains Abiraterone Acetate 250 mg Oral hormonal therapy for advanced prostate cancer Belongs to the CYP17 inhibitor class Helps reduce androgen production supporting cancer control Used as part of comprehensive prostate cancer treatment protocols Manufactured under strict pharmaceutical quality standards Suitable for oncology hospitals, clinics, and specialty healthcare providers Therapeutic Uses: Metastatic Castration-Resistant Prostate Cancer (mCRPC) Metastatic Castration-Sensitive Prostate Cancer (mCSPC), as recommended by an oncologist Note: Zabiteron Tablet should only be used under the direction of a qualified healthcare professional. Regular monitoring of liver function, blood pressure, potassium levels, and overall treatment response may be required during therapy.

PPTINIB Tablet contains Dasatinib, a prescription tyrosine kinase inhibitor (TKI) used in the treatment of certain types of leukemia. It works by blocking abnormal proteins (BCR-ABL and SRC family kinases) that promote the growth and spread of cancer cells, helping to slow or stop disease progression. Dasatinib is commonly prescribed for adults and children with Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and certain cases of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), as determined by an oncologist or hematologist. PPTINIB Tablets are manufactured under stringent quality standards and are available in multiple strengths to meet different treatment requirements. The tablets should be taken exactly as prescribed by a healthcare professional, with or without food, and treatment should not be discontinued without medical advice. Key Highlights Brand Name: PPTINIB Tablet Generic Name: Dasatinib Dosage Form: Oral Tablets Therapeutic Category: Anti-Cancer / Oncology Medicine Drug Class: Tyrosine Kinase Inhibitor (TKI) Indications: Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Storage: Store below 30°C in a cool, dry place away from direct sunlight. Prescription Status: Prescription-only medicine. Use only under the supervision of a qualified healthcare professional.

Peg Zuvigrast (Pegfilgrastim Injection 6 mg) belongs to the Supportive Cancer Care category and is used to help reduce the risk of chemotherapy-induced neutropenia, a condition in which white blood cell counts become dangerously low after cancer treatment. Pegfilgrastim is a long-acting Granulocyte Colony-Stimulating Factor (G-CSF) that stimulates the bone marrow to produce neutrophils, helping the body fight infections during chemotherapy. This category includes Pegfilgrastim 6 mg injections intended for use in oncology hospitals, cancer treatment centers, specialty clinics, and licensed pharmacies. The medicine is typically administered under the supervision of qualified healthcare professionals as part of supportive care for patients receiving myelosuppressive chemotherapy. Our selection of Pegfilgrastim injections is manufactured in WHO-GMP compliant facilities and is available for international pharmaceutical export, wholesale distribution, and institutional procurement. Products are supplied with secure packaging and reliable worldwide shipping in accordance with applicable export regulations. Category Highlights Long-acting Pegfilgrastim (G-CSF) injection for supportive cancer care Helps reduce the risk of chemotherapy-induced neutropenia and febrile neutropenia 6 mg/0.6 mL prefilled syringe formulation Manufactured in WHO-GMP compliant pharmaceutical facilities Suitable for hospitals, oncology clinics, specialty pharmacies, and distributors Available for wholesale, institutional supply, and international export Secure packaging and reliable global shipping Prescription-only medicine to be used under the supervision of qualified healthcare professionals.

PEG-Asparaginase (Peg L-Asparaginase) Injection is an oncology medicine used as part of combination chemotherapy protocols for the treatment of Acute Lymphoblastic Leukemia (ALL) and certain other hematologic malignancies. It is a pegylated form of the enzyme L-asparaginase that works by depleting the amino acid L-asparagine, which leukemia cells require for growth and survival. Because healthy cells can produce their own asparagine while many leukemia cells cannot, PEG-Asparaginase selectively inhibits the growth of malignant cells. This category includes high-quality PEG L-Asparaginase injections manufactured in WHO-GMP compliant facilities and intended for use by hospitals, oncology centers, specialty pharmacies, and licensed healthcare providers. The medicine is administered by qualified healthcare professionals according to established chemotherapy protocols and requires careful patient monitoring due to the potential for serious adverse reactions. Our range of PEG-Asparaginase injections is available for international export, wholesale supply, and pharmaceutical distribution, with secure packaging and reliable worldwide shipping to eligible destinations in accordance with applicable regulations. Category Highlights: Pegylated L-Asparaginase injections for oncology treatment Used in combination chemotherapy for Acute Lymphoblastic Leukemia (ALL) WHO-GMP quality manufacturing Suitable for hospitals, oncology clinics, and specialty pharmacies Available for wholesale and international pharmaceutical export Secure packaging with reliable global shipping Prescription-only medicine to be administered under specialist medical supervision

Meracaptaz 50 mg contains Melphalan, an alkylating anticancer medicine used in the treatment of certain blood cancers and other selected malignancies. It works by damaging the DNA of rapidly dividing cancer cells, helping to slow or stop their growth. Melphalan tablets are prescribed only under the supervision of an experienced oncologist due to the risk of severe bone marrow suppression and the need for close monitoring. Key Benefits Helps treat specific cancers by inhibiting cancer cell growth. Oral tablet for convenient administration when prescribed. Commonly used in established chemotherapy protocols. May be used alone or in combination with other anticancer medicines. Treatment is individualized based on the patient's condition and response. Indications Meracaptaz (Melphalan Tablets) may be prescribed for: Multiple myeloma Ovarian cancer Other oncology indications as determined by the treating oncologist and local treatment guidelines. How It Works Melphalan belongs to the alkylating agent class of chemotherapy medicines. It forms cross-links with DNA, preventing cancer cells from replicating and dividing, which ultimately leads to cancer cell death. Dosage & Administration Take only as prescribed by your oncologist. Swallow the tablet whole with water. The dose depends on the type of cancer, body condition, and blood test results. Regular blood tests are essential during treatment to monitor blood cell counts and organ function. Do not change or stop the medication without medical advice. Possible Side Effects Common side effects may include: Low white blood cell count (neutropenia) Low platelet count (thrombocytopenia) Anemia Nausea and vomiting Loss of appetite Mouth sores Fatigue Increased risk of infections Seek immediate medical attention if you develop fever, unusual bleeding, severe bruising, persistent vomiting, or signs of a serious infection.